Table 3 Selected dose modifications during induction therapy
| Adverse Reaction | Occurrence | Paclitaxel Dose (mg/m2) | Carboplatin Dose (AUC mg·min/mL) |
|---|---|---|---|
| Hematologic | |||
| ANC < 1500/mm3 OR ANC < 500/mm3 for more than 7 days | First | 75 | 4.5 |
| Second | 50 | 3 | |
| Third | Discontinue Treatment | ||
| Platelet count less than 100,000/mm3 | First | 75 | 4.5 |
| Second | Discontinue Treatment | ||
| Neurotoxicity (Peripheral) | |||
| Grade 2 | First | 75 | |
| Second | 50 | ||
| Third | Discontinue Treatment | ||
| Grade 3–4 | First | Withhold paclitaxel, until improves to < = grade 1, then resume at one lower dose level | |